poisar

Stocks · News reference

Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT

Benzinga Newsdesk

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

INBX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

    DelveInsight released a comprehensive report on the chondrosarcoma clinical trial pipeline, highlighting 5+ emerging therapies in development by key players. Notable drugs include Ozekibart (INBRX-109) which received FDA acceptance for filing with a PDUFA goal date of April 2027, Ivosidenib in Phase III trials, and RBT-102 in preclinical stages. The pipeline focuses on novel mechanisms including DR5 agonism and IDH1 inhibition to address this rare, high-unmet-need oncology market.

    INBX